Abstract
Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Current Drug Discovery Technologies
Title: Passive and Active Tumour Targeting with Nanocarriers
Volume: 8 Issue: 3
Author(s): Samuli Hirsjarvi, Catherine Passirani and Jean-Pierre Benoit
Affiliation:
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Abstract: Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Export Options
About this article
Cite this article as:
Hirsjarvi Samuli, Passirani Catherine and Benoit Jean-Pierre, Passive and Active Tumour Targeting with Nanocarriers, Current Drug Discovery Technologies 2011; 8 (3) . https://dx.doi.org/10.2174/157016311796798991
DOI https://dx.doi.org/10.2174/157016311796798991 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem cells contributing to postnatal skeletogenesis in the mouse bone marrow
Current Stem Cell Research & Therapy Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain
Current Neuropharmacology Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry Targeting Glia Cells: Novel Perspectives for the Treatment of Neuropsychiatric Diseases
Current Neuropharmacology Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Arylpyrazoles: Heterocyclic Scaffold of Immense Therapeutic Application
Current Organic Chemistry Geniposide Attenuates Mitochondrial Dysfunction and Memory Deficits in APP/PS1 Transgenic Mice
Current Alzheimer Research Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting
Current Molecular Medicine G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Clinical and <i>In Silico</i> Outcomes of the Expression of miR-130a-5p and miR-615-3p in Tumor Compared with Non-Tumor Adjacent Tissues of Patients with BC
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Medicinal Chemistry Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Fluorescence Molecular Imaging of Small Animal Tumor Models
Current Molecular Medicine